Biohope receives EU funds in the “SME instrument” of the H2020 program.

Biohope announces the success of its application for a European project in the cut-off for the Phase 1 SME-instrument in the H2020 program (score: 14.19).

Biohope receives 50.000€ for accomplishing a feasibility study so to evaluate the technical viability of developing its proprietary technology and to assess its commercial potential. This Phase 1 will also give Biohope access to business coaching services offered by the European Commission.

The SME instrument is part of the Horizon 2020 program and finances innovative ideas with great social impact and market potential. The instrument is divided in three phases, with the aim of transforming disruptive ideas into concrete, innovative solutions with a European and global impact.

In the SME-instrument financing scheme, the successful applicants in Phase 1 are the preferential candidates to opt for a Phase 2 project of between €0.5-3M funding.

This peer-reviewed fund confirms the expectations and extraordinary possibilities of our diagnostic/therapeutic approach not just to produce useful clinical information, but also to enforce development of diagnostic kits and potential therapies for kidney transplantation tolerance induction.

2016-10-18T13:01:00+00:00November 29th, 2015|Research|Comments Off on Biohope receives EU funds in the “SME instrument” of the H2020 program.